Anti-Osteoprotegerin 抗体 (ab10962)


  • 製品名
    Anti-Osteoprotegerin antibody
    Osteoprotegerin 一次抗体 製品一覧
  • 製品の詳細
    Goat polyclonal to Osteoprotegerin
  • 特異性
    By immunoblotting (non-reducing), the antibody shows approximately 25% cross-reactivity with recombinant human OPG.
  • アプリケーション
    適用あり: ELISA, WB, Neutralisingmore details
  • 種交差性
    交差種: Mouse
    交差が予測される動物種: Rat, Human
  • 免疫原

    Recombinant full length protein (Mouse) expressed in mouse NSO cells.

  • 特記事項
    Do not store in a frost-free freezer. Endotoxin level is < 10 ng/mg antibody as determined by the LAL (Limulus amebocyte lysate) method.



Our Abpromise guarantee covers the use of ab10962 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
  • 追加情報
    ELISA: Use at a concentration of 0.5 - 1 µg/ml. The detection limit for mouse osteoprotegerin is approximately 0.1 ng/well.
    Neut: To measure the ability of the antibody to neutralize the bioactivity of mouse OPG, soluble recombinant mouse OPG/Fc is incubated with various concentrations of the antibody in media containing actinomycin D for 1 hour at 37 °C in 96 well plates.
    WB: Use at a concentration of 1 - 2 µg/ml. This concentration detects mouse OPG at approximately 2 ng/lane and 5 ng/lane under nonreducing and reducing conditions, respectively. Reduced mouse OPG/Fc chimera has a calculated molecular mass of approximately 70.9 kDa. As a result of glycosylation, the recombinant protein migrates as a 100 kDa band in SDS-PAGE under reducing conditions.

    Cross-linked recombinant human TRAIL is then added and incubated for an additional 30 minutes. Following preincubation, the mixture is added to confluent cultures of L929 cells in 96 well plates. The assay mixture (total volume of 150 µl/well) over a monolayer of L929 cells containing antibody (concentrations of 0.01-100 µg/ml), soluble recombinant mouse OPG/Fc (0.1 µg/ml), actinomycin D (1 µg/ml), and cross-linked human TRAIL (20 ng/ml) is incubated at 37 °C for 24 hours in a humidified CO2 incubator. At the end of the incubation period, the media is removed and the cells are fixed with 5% formaldehyde and then stained with crystal violet. The stain is subsequently dissolved in 100 µl of 33% acetic acid and the optical density is read at 540 nm.

    The Neutralization Dose50 (ND50) for anti-mouse osteoprotegerin is 0.5-2 µg/ml in the presence of 0.1 µg/ml of soluble recombinant mouse OPG/Fc, using the TRAIL sensitive mouse L929 cytolytic assay. The ND50 is the concentration of antibody required to yield one-half maximal inhibition of the cytokine activity on a responsive cell line, when the cytokine is present at a concentration just high enough to elicit a maximum response. The exact concentration of antibody required to neutralize recombinant mouse OPG/Fc activity is dependent on the cytokine concentration, cell type, growth conditions, and the type of activity studied.

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • ターゲット情報

    • 機能
      Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.
    • 組織特異性
      Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.
    • 関連疾患
      Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal.
    • 配列類似性
      Contains 2 death domains.
      Contains 4 TNFR-Cys repeats.
    • 翻訳後修飾
      N-glycosylated. Contains sialic acid residues.
      The N-terminus is blocked.
    • 細胞内局在
    • Information by UniProt
    • 参照データベース
    • 別名
      • MGC29565 antibody
      • OCIF antibody
      • OPG antibody
      • Osteoclastogenesis inhibitory factor antibody
      • Osteoprotegerin antibody
      • PDB5 antibody
      • TNF receptor superfamily member 11b antibody
      • TNFRSF 11B antibody
      • TNFRSF11B antibody
      • TR 1 antibody
      • TR1 antibody
      • TR11B_HUMAN antibody
      • Tumor necrosis factor receptor superfamily member 11B antibody
      see all



    ab10962 has not yet been referenced specifically in any publications.

    レビューと Q&A

    I have received confirmation that these 3 replacement vials will be included in the next shipment to Aurogene. I hope this is helpful. Please contact me again if you have any further questions.

    Thanks for your reply. It seems that, as part of their own internal QC, the customer has already peformed the control I suggested. This is great as it does appear clear now that these 3 antibodies are not working as expected. I would be happy to reques...

    Read More

    Thank you for providing the additional information. The one thing I would like to recommend in this case is to run a "loading control" western blot with the murine osteoblast cell lysate. Examples of targets for this type of control would be proteins t...

    Read More

    Thank you for your enquiry. Sorry to hear your customer's are having trouble with these antibodies.   What species of bone cells were being tested? What dilution of primary antibody for each? Was any other antibody used successfully with these same sam...

    Read More